General American Investors Co. Inc. Has $5.15 Million Stock Position in Maravai LifeSciences Holdings, Inc. $MRVI

General American Investors Co. Inc. increased its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 1,062.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 1,585,316 shares of the company’s stock after acquiring an additional 1,448,907 shares during the period. General American Investors Co. Inc.’s holdings in Maravai LifeSciences were worth $5,152,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of MRVI. Monaco Asset Management SAM grew its position in shares of Maravai LifeSciences by 315.0% during the 3rd quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock worth $10,494,000 after buying an additional 2,775,372 shares during the period. First Eagle Investment Management LLC grew its position in shares of Maravai LifeSciences by 299.0% during the 4th quarter. First Eagle Investment Management LLC now owns 1,799,336 shares of the company’s stock worth $5,848,000 after buying an additional 1,348,405 shares during the period. Marshall Wace LLP grew its position in shares of Maravai LifeSciences by 52.3% during the 4th quarter. Marshall Wace LLP now owns 2,000,278 shares of the company’s stock worth $6,501,000 after buying an additional 687,253 shares during the period. Tejara Capital Ltd grew its position in shares of Maravai LifeSciences by 23.1% during the 4th quarter. Tejara Capital Ltd now owns 3,020,209 shares of the company’s stock worth $9,816,000 after buying an additional 566,768 shares during the period. Finally, Royce & Associates LP grew its position in shares of Maravai LifeSciences by 38.0% during the 3rd quarter. Royce & Associates LP now owns 1,761,764 shares of the company’s stock worth $5,056,000 after buying an additional 484,908 shares during the period. 50.25% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total transaction of $126,500.00. Following the transaction, the general counsel owned 360,767 shares in the company, valued at $1,825,481.02. The trade was a 6.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is owned by company insiders.

Maravai LifeSciences Trading Down 4.4%

NASDAQ:MRVI opened at $4.98 on Friday. Maravai LifeSciences Holdings, Inc. has a fifty-two week low of $1.99 and a fifty-two week high of $5.30. The company has a debt-to-equity ratio of 0.72, a current ratio of 5.91 and a quick ratio of 4.96. The stock has a market capitalization of $1.29 billion, a PE ratio of -7.01 and a beta of 0.72. The business’s 50-day simple moving average is $4.06 and its 200-day simple moving average is $3.65.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.06. Maravai LifeSciences had a negative return on equity of 17.87% and a negative net margin of 51.07%.The business had revenue of $65.84 million for the quarter, compared to analysts’ expectations of $53.00 million. Sell-side analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on MRVI shares. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $6.00 target price on shares of Maravai LifeSciences in a research report on Friday, May 8th. Wells Fargo & Company boosted their target price on Maravai LifeSciences from $4.50 to $5.50 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Wall Street Zen upgraded Maravai LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, May 23rd. UBS Group restated a “reduce” rating on shares of Maravai LifeSciences in a research report on Wednesday, June 3rd. Finally, Weiss Ratings upgraded Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 29th. Three analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $5.50.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.